- Tumor removal doesn’t help patients live longer
- Helps people with cancer spread to multiple organs
- Not ready for use—may change current practice
This large study shows that removing tumors in advanced colon cancer doesn’t help people live longer.
You’ve just been told your colon cancer has spread. Your doctor says chemo can help. But some hospitals also offer surgery or radiation to remove visible tumors. You wonder: Will that give me more time?
Now, a major study gives a clear answer—for most people, it won’t.
Colon cancer is one of the most common cancers worldwide. When it spreads to other organs—like the liver or lungs—it’s called metastatic.
Most patients get chemo to slow the cancer. But over time, some doctors began adding surgery or ablation (destroying tumors with heat or cold) to remove as much cancer as possible.
The idea made sense: Less tumor = better outcome. But until now, no large trial proved it actually helped people live longer.
Fewer tumors, same survival
For years, doctors believed that removing visible tumors could help patients live longer. This idea, called “debulking,” became popular—especially when scans showed the cancer responding to chemo.
But here’s the twist: The new study found that even after removing tumors, patients lived about the same amount of time as those who only had chemo.
What scientists didn’t expect
Many experts thought cutting out tumors would give patients a survival edge. After all, less cancer in the body should mean better outcomes.
But the body is more complex than that. Even when doctors remove visible tumors, tiny cancer cells often remain. These can grow back later—like weeds after pulling the big ones.
Think of cancer like a forest fire. Chemo is like water from a plane—it slows the flames. Surgery is like sending crews to clear trees in one spot.
It looks better on the map. But if embers are still smoldering underground, the fire will return.
That’s what may be happening here. Removing visible tumors doesn’t stop the disease process already in motion.
The surprising shift
This trial, called ORCHESTRA, followed 382 patients across 28 hospitals in Europe. All had colon cancer that had spread to more than one organ.
First, everyone got a few rounds of chemo. If the cancer shrank or stayed stable, patients were randomly assigned to either keep chemo alone—or have surgery, radiation, or ablation to remove tumors, then continue chemo.
Patients who had their tumors removed lived 30 months on average. Those who only had chemo lived 27.5 months.
That’s a small difference—just 2.5 months. And it wasn’t big enough to say the added treatment helped. Statistically, it could have been due to chance.
Progression-free survival—the time before cancer worsened—was nearly identical. 10.4 months with chemo alone. 10.5 months with chemo plus tumor removal.
No meaningful gain.
But there’s a catch. More patients who had tumor removal had serious side effects.
Over half (53%) had a major health issue after surgery or ablation. Only 39% of those on chemo alone had similar problems.
That means added risk, without added benefit.
This doesn’t mean this treatment is available yet.
This study challenges a growing trend in cancer care. While local treatments like surgery or ablation can help in select cases—like when a tumor is causing pain or blockage—this trial shows they don’t extend life when used broadly in multiorgan disease.
It suggests that for most patients, focusing on systemic treatment—like chemo or targeted drugs—may be smarter than chasing visible tumors.
If you or a loved one has advanced colon cancer, this study suggests that opting for extra surgeries or ablations may not help you live longer.
It’s okay to ask your doctor: Will this actually extend my life—or just add risk? Shared decision-making, based on strong evidence, is key.
The fine print
The study only looked at patients whose tumors responded to initial chemo. Results might be different for those with stable or growing disease.
Also, all patients were treated in Europe. Practices may vary in other countries.
And while the trial was large, it wasn’t designed to study every subgroup—like patients with only liver or only lung metastases.
What happens next
Doctors may rethink how often they recommend surgery or ablation for widespread colon cancer.
Future research could focus on who might still benefit—like patients with very limited spread or special tumor types.
For now, chemo remains the backbone of care. And less invasive doesn’t always mean better. Sometimes, the best move is no surgery at all.
